Published Date: 23 Aug 2024
Lazertinib plus amivantamab improved PFS by about 7 months versus single-agent osimertinib
Read Full NewsThree medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.
Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.
1.
Prostate Cancer Treatment Associated With Long-Term Complications
2.
Targeted radiation offers promise in patients with metastasized small cell lung cancer to the brain
3.
Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.
4.
Study looks into cancer-related harmful communication.
5.
NEET SS Counseling 2023: MCC provides information on DNB SS Medical Oncology seats available at ESIC Medical College and Hospital Faridabad.
1.
Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support
2.
What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide
3.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
4.
Matrix Metalloproteinases in Stroke: Broad vs. Selective Inhibition Strategies
5.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
3.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation